Neoadjuvant intraarterial high-dose chemotherapy and autologous peripheral blood stem cell transplantation for advanced breast cancer.
Eight locally advanced breast cancer patients were treated with neoadjuvant intraarterial high-dose chemotherapy (epirubicin) plus MPA combined with autologous PBSCT. All patients completed the scheduled treatment, and there were no toxic deaths. Patients were treated with an escalating dose of epirubicin (370-480 mg) and cyclophosphamide (0-6000 mg). The rate of clinical response was 100%. The rate of good histologic response was 87.5% in the main tumor and 75% in diseased lymph nodes. The 2-year survival rate was 100%. Six patients were disease-free at the time of writing. This treatment resulted in higher rates of clinical and histologic response when compared with standard-dose intraarterial chemotherapy.
Yagihashi
A
A
Department of Laboratory Diagnosis, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan.
Okazaki
M
M
Hirata
K
K
Ohmura
T
T
Okazaki
A
A
Suzuki
Y
Y
Yuyama
Y
Y
Okamoto
J
J
Wada
Y
Y
Yajima
T
T
Kameshima
H
H
Araya
J
J
Yanai
Y
Y
Endoh
T
T
Watanabe
N
N
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D003131:Combined Modality Therapy; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D008875:Middle Aged; D016019:Survival Analysis; D014182:Transplantation, Autologous
D015251:Epirubicin; D017258:Medroxyprogesterone Acetate